Skip to content

European Commission

ERA4Health Joint Transnational Call – IICS4all

Deadline: 14 January 2027 (in 56 days)

Last seen in a scan/import: .

Catalog updated: .

These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.

Closes 14 Jan 2027. Add it to your calendar, then see what else you're eligible for. Check my fit for this call →

The ERA4Health IICS4all Joint Transnational Call funds multi-national Investigator-Initiated Clinical Studies in cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases. It targets pragmatic comparative effectiveness trials and drug repurposing studies of off-patent drugs, run by transnational consortia of clinical and public health researchers, with attention to underrepresented populations. The call runs annually under the European Commission's ERA4Health partnership.

Details

Funder European Commission
Deadline 14 January 2027
Consortium Required — multi-national consortium of clinical/public health teams conducting transnational Investigator-Initiated Clinical Studies across multiple countries
Frequency Annual

Eligibility & scope

Funds multi-national Investigator-Initiated Clinical Studies (IICS) in cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases, including underrepresented populations. Studies should be pragmatic comparative effectiveness and/or drug repurposing trials of off-patent drugs demonstrating transnational collaboration across countries.

Who Should Apply

  • •Clinical and public health researchers leading investigator-initiated trials
  • •Multi-national consortia spanning clinical research teams across countries
  • •Research focus on cardiovascular, autoimmune, metabolic or non-communicable respiratory disease
  • •Teams designing pragmatic comparative effectiveness or drug repurposing trials of off-patent drugs
  • •Studies including underrepresented patient populations

Key Dates

  • •Deadline: 14 January 2027
  • •Call runs annually under ERA4Health

Tips for Applicants

  • ✓Frame the trial design explicitly as pragmatic comparative effectiveness or drug repurposing, the call excludes standard drug-development trials.
  • ✓Build the consortium around off-patent drug use cases, since novel compound trials fall outside scope.
  • ✓Show concrete inclusion of underrepresented populations in the study design, not just as a stated aim.

Frequently Asked Questions

What diseases does the ERA4Health IICS4all call fund?

Cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases, including studies involving underrepresented populations.

What type of clinical studies does IICS4all support?

Pragmatic comparative effectiveness trials and drug repurposing trials of off-patent drugs led by investigators rather than industry.

Is a consortium required for ERA4Health IICS4all?

Yes, applicants must form a multi-national consortium of clinical and public health teams conducting the study across multiple countries.

When is the ERA4Health IICS4all deadline?

The deadline is 14 January 2027, and the call runs annually.

clinical-trialscardiovascular-diseaseautoimmune-diseasemetabolic-diseaserespiratory-diseaseera4healthconsortium-requireddrug-repurposing

Related on Grantsby

Summary generated by AI based on published grant information. Always verify details on the funder's website.

Similar grants

Browse all open grants →

Browse Related

Could ERA4Health Joint Transnational Call – IICS4all be right for you?

See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.

See my matches free →